Alcon Canada adds
innovative dry eye
treatment to its
portfolio
HAVE YOU ASKED YOUR PATIENTS
HOW THEIR EYES ARE FEELING TODAY?
BETWEEN INCREASED SCREEN TIME AND
LONGER WORKDAYS, CHANCES ARE THEY
ARE AMONG THE 6 MILLION CANADIANS 1
LIVING WITH DRY EYE DISEASE OR
EXPERIENCING DRY EYE SYMPTOMS.
According to a recent survey by research
firm Leger on behalf of Alcon Canada, 85
per cent of Canadians have experienced
at least one symptom of dry eye, which
can include eye fatigue, watery eyes,
sensitivity to light, blurred vision, eye redness,
and difficulty with nighttime driving. 2
Those who suffer from dry eye say
activities like reading, driving and
travelling can increase the problem.
Of Canadians with dry eye:
58% say they
experience
more dry eye
discomfort
depending
on the
season
67% say their
eyes get tired
when looking
at computer,
phone, tablet
or television
screens
66% say
they
experience
dry eye
symptoms
when they
read
“Dry eye is a chronic issue for a large
number of my patients, making it a
challenge to treat them and achieve
optimal results,” said Dr. Judy Parks,
doctor of optometry at Ancaster Eye
Clinic. “This can be caused by factors
such as normal aging, hormonal changes,
environmental exposure, medical
conditions, and excessive screen time,
making it important to treat the root
cause of your patients’ dry eye in addition
to addressing its symptoms.”
Considering the
unique and prevalent
impact of dry eye across
the general public, Alcon Canada has
added the iLux® MGD Treatment System
– an innovative, handheld device for
the treatment of Meibomian Gland
Dysfunction (MGD) – to its robust
selection of dry eye treatment options.
“Alcon Canada is continuously exploring
new ways to innovate dry eye treatment,
address patient needs, and broaden
dry eye awareness,” said Chris Van Dyk,
Country Business Head, Vision Care at
Alcon Canada. “This includes making
new additions to our market-leading
SYSTANE® product portfolio, as well as the
acquisition of the iLux® MGD Treatment
System, an in-office therapy for the
comprehensive treatment of dry eye.”
An innovative, in-office therapy
More than 85 per cent of patients with
dry eye have signs of MGD, making it a
major cause of dry eye. 3 Like other forms
of dry eye, MGD is associated with a
range of symptoms that can negatively
affect patients, including ocular
discomfort and blurry vision. 4 The iLux®
MGD Treatment System allows eye care
professionals to directly target a patient’s
blocked Meibomian glands and provide
therapy in-office.